Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
ZVSA Stock Chart & Stats
$0.14
-$0.05(-3.87%)
At close: 4:00 PM EST
$0.14
-$0.05(-3.87%)
Day’s Range― - ―
52-Week Range$0.11 - $1.95
Previous CloseN/A
Volume38.43K
Average Volume (3M)51.59K
Market Cap
$1.08M
Enterprise Value$609.90K
Total Cash (Recent Filing)$527.98K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.14
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue23.39
Enterprise Value/Gross Profit46.78
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.11 and its highest was $1.95 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $1.08M.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 97 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on Nov 19, 2025. The company reported -$2.56 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.56.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$2.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics (ZVSA) is a clinical stage specialty biopharmaceutical company focused on developing innovative therapies to address unmet needs in the areas of renal and inflammatory diseases. The company leverages its proprietary technologies to advance a portfolio of drug candidates aimed at improving patient outcomes and quality of life. ZyVersa's core product candidates include VAR 200 for kidney diseases and IC 100 for inflammatory conditions, which are in various stages of clinical development.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Conduit Pharmaceuticals
―
Ownership Overview
6.64%
Insiders
<0.01% Other Institutional Investors
93.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---